Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent Deferred RevenueCurrent LeasesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Tandem Diabetes Care (TNDM) Cash & Equivalents (2016 - 2025)

Historic Cash & Equivalents for Tandem Diabetes Care (TNDM) over the last 14 years, with Q3 2025 value amounting to $91.9 million.

  • Tandem Diabetes Care's Cash & Equivalents rose 8749.77% to $91.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was $91.9 million, marking a year-over-year increase of 8749.77%. This contributed to the annual value of $69.2 million for FY2024, which is 1760.89% up from last year.
  • Latest data reveals that Tandem Diabetes Care reported Cash & Equivalents of $91.9 million as of Q3 2025, which was up 8749.77% from $64.1 million recorded in Q2 2025.
  • In the past 5 years, Tandem Diabetes Care's Cash & Equivalents registered a high of $172.5 million during Q4 2022, and its lowest value of $47.7 million during Q2 2024.
  • In the last 5 years, Tandem Diabetes Care's Cash & Equivalents had a median value of $91.9 million in 2025 and averaged $91.5 million.
  • In the last 5 years, Tandem Diabetes Care's Cash & Equivalents soared by 14236.38% in 2022 and then tumbled by 6587.7% in 2023.
  • Quarter analysis of 5 years shows Tandem Diabetes Care's Cash & Equivalents stood at $71.2 million in 2021, then skyrocketed by 142.36% to $172.5 million in 2022, then plummeted by 65.88% to $58.9 million in 2023, then grew by 17.61% to $69.2 million in 2024, then skyrocketed by 32.81% to $91.9 million in 2025.
  • Its last three reported values are $91.9 million in Q3 2025, $64.1 million for Q2 2025, and $53.6 million during Q1 2025.